Preventing blood clots in genitourinary cancer with rivaroxaban
Treatments studied
Part of Cancer, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an active bladder, testis, ureter/renal pelvis, kidney, urethra, or penis cancer (but not prostate cancer), and you’re starting treatment
- You’re age 18 or older
- You plan to start systemic cancer therapy (chemo, targeted therapy, anti-cancer immunotherapy), and it’s expected to last at least 8 weeks
- You do not need blood thinners for another reason during the study (prevention or treatment dosing)
- You can take rivaroxaban safely—no known allergy, no major drug interactions that affect rivaroxaban, and kidney function is not severely reduced
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a lower dose of the blood thinner apixaban (Eliquis) can safely prevent another blood clot in people with cancer who have a catheter-related clot in their upper arm or neck. It aims to find a balance between preventing clots and reducing bleeding risk.
This trial is testing a program to help prevent blood clots in people with cancer who are starting a new type of cancer treatment, like chemotherapy or targeted therapy. The goal is to see if better prevention strategies can keep you safe during treatment.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
This trial tests whether a blood thinner called rivaroxaban (a pill) works well for older Chinese patients who have had a blood clot in their lungs and are now on long-term treatment. It aims to see if it's safe and effective for this group.
This trial tests whether a daily statin (rosuvastatin) can help prevent dangerous blood clots in people with advanced cancer who are starting new cancer therapy. It is for those at medium or high risk for clots, based on a simple risk score.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.